Charles Chrisawn

Oct 19, 2023 | clinicalleader.com | Peter H. Calcott |Daniel Eisenman |Charles Chrisawn |Michael Edwards

Medidata has a seat at the table where regulatory change happens. Our input helps accelerate your innovations into the marketplace. FDA Introduces Quality Management Maturity ProgramThe FDA program, described in a recent CDER document, is a next logical step to drive better quality, more predictable outcomes, and supply chain assurance.

Oct 10, 2023 | clinicalleader.com | Charles Chrisawn |Michael Edwards |Matthew Nowland

Get more clinical research insight with our FREE newsletter Article | October 10, 2023 By Charles Chrisawn, Michael Edwards and Matthew Nowland Cancer stands as the foremost global cause of mortality, responsible for nearly one out of every six deaths. Recent research indicates that approximately 15% of cancer-related fatalities could be prevented through early disease detection.

Oct 10, 2023 | cellandgene.com | Charles Chrisawn |Michael Edwards |Matthew Nowland

Article | October 10, 2023 By Charles Chrisawn, Michael Edwards and Matthew Nowland Cancer stands as the foremost global cause of mortality, responsible for nearly one out of every six deaths. Recent research indicates that approximately 15% of cancer-related fatalities could be prevented through early disease detection.

Sep 21, 2023 | clinicalleader.com | Michael Edwards |Matthew Nowland |Charles Chrisawn

Article | September 21, 2023 By Charles Chrisawn, Michael Edwards and Matthew Nowland The development of liquid biopsies for early cancer detection demands meticulous planning. Achieving success in this endeavor relies on a comprehensive grasp of the regulatory landscape and the hurdles involved in conducting the requisite studies for approval.